Zosano Pharma (Zosano Pharma) Cash Flow from Financing : $17.57 Mil (TTM As of Mar. 2022)

View and export this data going back to 2015. Start your Free Trial

What is Zosano Pharma Cash Flow from Financing?

Cash from financing is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders.

For the three months ended in Mar. 2022, Zosano Pharma received $14.20 Mil more from issuing new shares than it paid to buy back shares. It received $0.00 Mil from issuing more debt. It paid $0.00 Mil more to buy back preferred shares than it received from issuing preferred shares. It received $0.00 Mil from paying cash dividends to shareholders. It spent $3.11 Mil on other financial activities. In all, Zosano Pharma earned $11.09 Mil on financial activities for the three months ended in Mar. 2022.

Zosano Pharma Cash Flow from Financing Historical Data

The historical data trend for Zosano Pharma's Cash Flow from Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zosano Pharma Cash Flow from Financing Chart

Zosano Pharma Annual Data

Trend

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Cash Flow from Financing

Get a 7-Day Free Trial

25.00

45.82

29.83

69.15

8.79

Zosano Pharma Quarterly Data
	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22
Cash Flow from Financing	Get a 7-Day Free Trial															2.32	4.35	2.00	0.14	11.09

Zosano Pharma Cash Flow from Financing Calculation

This is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders. In the calculation of free cash flow, cash from financing is not calculated because it is not related to operating activities.

Zosano Pharma's Cash from Financing for the fiscal year that ended in Dec. 2021 is calculated as:

	Cash Flow from Financing		(A: Dec. 2021 )
=	Issuance of Stock	+	Repurchase of Stock	+	Net Issuance of Debt	+	Net Issuance of Preferred Stock	+	Cash Flow for Dividends	+	Other Financing
=	10.216	+	0	+	0	+	0	+	0	+	-1.423
=	8.79

Zosano Pharma's Cash from Financing for the quarter that ended in Mar. 2022 is:

	Cash Flow from Financing		(Q: Mar. 2022 )
=	Issuance of Stock	+	Repurchase of Stock	+	Net Issuance of Debt	+	Net Issuance of Preferred Stock	+	Cash Flow for Dividends	+	Other Financing
=	14.203	+	0	+	0	+	0	+	0	+	-3.112
=	11.09

Cash Flow from Financing for the trailing twelve months (TTM) ended in Mar. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $17.57 Mil.

Zosano Pharma (OTCPK:ZSANQ) Cash Flow from Financing Explanation

Cash from financing contains six items:

1. Issuance of Stock:
A company may raise cash from issuing new shares. Issuance of stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.

Zosano Pharma's issuance of stock for the three months ended in Mar. 2022 was $14.20 Mil.

2. Repurchase of Stock:
A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of stock represents the cash outflow to reacquire common stock during the period.

Zosano Pharma's repurchase of stock for the three months ended in Mar. 2022 was $0.00 Mil.

3. Net Issuance of Debt:
Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.

Zosano Pharma's net issuance of debt for the three months ended in Mar. 2022 was $0.00 Mil. Zosano Pharma received $0.00 Mil from issuing more debt.

4. Net Issuance of Preferred Stock:
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.

Zosano Pharma's net issuance of preferred for the three months ended in Mar. 2022 was $0.00 Mil. Zosano Pharma paid $0.00 Mil more to buy back preferred shares than it received from issuing preferred shares.

5. Cash Flow for Dividends:
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.

Zosano Pharma's cash flow for dividends for the three months ended in Mar. 2022 was $0.00 Mil. Zosano Pharma received $0.00 Mil from paying cash dividends to shareholders.

6. Other Financing:
Money spent or earned by company from other financial activities.

Zosano Pharma's other financing for the three months ended in Mar. 2022 was $-3.11 Mil. Zosano Pharma spent $3.11 Mil on other financial activities.

Zosano Pharma Cash Flow from Financing Related Terms

Thank you for viewing the detailed overview of Zosano Pharma's Cash Flow from Financing provided by GuruFocus.com. Please click on the following links to see related term pages.

Zosano Pharma (Zosano Pharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zosano Pharma Corp (OTCPK:ZSANQ) » Definitions » Cash Flow from Financing

Comparable Companies

Traded in Other Exchanges

N/A

Address

34790 Ardentech Court, Fremont, CA, USA, 94555

Website

https://www.zosanopharma.com

Zosano Pharma Corp is a clinical-stage biopharmaceutical company. It is focused on providing rapid systemic administration of therapeutics and other bioactive molecules to patients using the proprietary transdermal microneedle system. The system is designed to facilitate rapid drug absorption into the bloodstream, which can result in an improved pharmacokinetic profile compared to original dosage forms. The company's operating segment is to develop human pharmaceutical products. Its primary product candidate is Qtrypta (M207) which is the proprietary formulation of zolmitriptan delivered utilizing the system.

Executives

Christine Matthews	officer: Chief Financial Officer	C/O ZOSANO PHAMA CORPORATION, 34790 ARDENTECH COURT, FREMONT CA 94555
Steven Lo	director, officer: Chief Executive Officer	C/O CORCEPT THERAPEUTICS, 149 COMMONWEALTH DRIVE, MENLO PARK CA 94010
Donald J Kellerman	officer: VP, Clinical Dev & Med Affairs	INSPIRE PHARMACEUTICALS, INC.,, 4222 EMPEROR BLVD., STE. 470, DURHAM NC 27703-8466
Elaine Yang	director	C/O ZOSANO PHARMA CORPORATION, 34790 ARDENTECH COURT, FREMONT CA 94555
Kenneth Greathouse	director	3260 WHIPPIE ROAD, UNION CITY CA 94587
Hayley Lewis	officer: See Remarks	C/O CARBYLAN THERAPEUTICS, INC., 3181 PORTER DRIVE, PALO ALTO CA 94304
Kathy M. Mcgee	director	C/O AVITA MEDICAL, 28159 AVENUE STANFORD, SUITE 220, VALENCIA CA 91355
Linda S Grais	director	86 ALEJANDRA AVE, ATHERTON CA 94027
Joseph P Hagan	director	3344 N. TORREY PINES COURT, SUITE 200, LA JOLLA CA 92037
Kleanthis G Xanthopoulos	director	9050 CAMINO SANTA FE, SAN DIEGO CA 92121
John Peter Walker	director	126 ISABELLA AVE, ATHERTON CA 94027
Aisling Capital Partners Iv, Lp	10 percent owner	888 SEVENTH AVENUE, 12TH FLOOR, NEW YORK NY 10106
Aisling Capital Partners Iv Llc	10 percent owner	888 SEVENTH AVENUE, 12TH FLOOR, NEW YORK NY 10106
Aisling Capital Iv, Lp	10 percent owner	888 SEVENTH AVENUE, 12TH FLOOR, NEW YORK NY 10106
Andrew N Schiff	10 percent owner	PLANET ZANETT INC, 135 E 57TH ST, NEW YORK NY 10022